Faron Pharmaceuticals aktie (FARON) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelanden från Faron Pharmaceuticals

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

GlobeNewswire • 16 May 16:01

Faron Confirms Plans for the Coming Months Under New Leadership

Faron Confirms Plans for the Coming Months Under New Leadership

GlobeNewswire • 16 Apr 08:00

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

GlobeNewswire • 18 Mar 14:00

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

GlobeNewswire • 14 Mar 08:00

Faron’s Financial Statement Release January 1 to December 31, 2023

Faron’s Financial Statement Release January 1 to December 31, 2023

GlobeNewswire • 13 Mar 08:00

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

GlobeNewswire • 25 Jan 08:00

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Faron Pharmaceuticals to Present at the 42nd Annual J.

GlobeNewswire • 03 Jan 08:00

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) A...

GlobeNewswire • 11 Dec 2023 08:00

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

GlobeNewswire • 07 Dec 2023 08:00

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

GlobeNewswire • 06 Nov 2023 08:00

Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register

Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register

GlobeNewswire • 27 Oct 2023 08:05

Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients

Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients

GlobeNewswire • 11 Oct 2023 13:00

Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months

Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Ne...

GlobeNewswire • 03 Oct 2023 08:00

Faron Pharmaceuticals Announces Board Changes

Faron Pharmaceuticals Announces Board Changes

GlobeNewswire • 22 Sep 2023 17:00

Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting

Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting

GlobeNewswire • 22 Sep 2023 12:33

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire • 06 Sep 2023 08:00

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

GlobeNewswire • 29 Aug 2023 06:01

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

GlobeNewswire • 29 Aug 2023 06:00

Faron Pharmaceuticals Notice of Half-Year Financial Results

Faron Pharmaceuticals Notice of Half-Year Financial Results

GlobeNewswire • 04 Aug 2023 14:00

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML ...

GlobeNewswire • 19 Jul 2023 10:54

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update

GlobeNewswire • 19 Jul 2023 09:00